Notice for durvalumab (AstraZeneca Pty Ltd)
Active ingredients
durvalumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platin-based chemoradiation therapy
Therapeutic area
Oncology